Skip to main content

CORRECTION article

Front. Med., 04 June 2024
Sec. Gene and Cell Therapy
Volume 11 - 2024 | https://doi.org/10.3389/fmed.2024.1416622

Corrigendum: PCSK9i promoting the transformation of AS plaques into a stable plaque by targeting the miR-186-5p/Wipf2 and miR-375-3p/Pdk1/Yap1 in ApoE–/– mice

This article is a correction to:

  1. PCSK9i promoting the transformation of AS plaques into a stable plaque by targeting the miR-186-5p/Wipf2 and miR-375-3p/Pdk1/Yap1 in ApoE−/− mice

    1. Read original article
\r\nYanlong ZhaoYanlong Zhao1Ning LiuNing Liu1Jifeng ZhangJifeng Zhang2Lei Zhao Lei Zhao1*
  • 1Department of Cardiology, The Second Hospital of Jilin University, Changchun, Jilin, China
  • 2School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin, China

A corrigendum on
PCSK9i promoting the transformation of AS plaques into a stable plaque by targeting the miR-186-5p/Wipf2 and miR-375-3p/Pdk1/Yap1 in ApoE–/– mice

by Zhao, Y., Liu, N., Zhang, J., and Zhao, L. (2024). Front. Med. 11:1284199. doi: 10.3389/fmed.2024.1284199

In the published article, there was an error in the Funding statement. The funding statement for the Department of Finance of Jilin Province, China was displayed as “3D5204920429”. The correct statement is “Department of Finance of Jilin Province, China (No. 2020SCZT043).” The correct Funding statement appears below.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was financially supported by grants from the Department of Finance of Jilin Province, China (No. 2020SCZT043).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: atherosclerosis, PCSK9i, miRNA, atorvastatin, atherosclerotic plaque

Citation: Zhao Y, Liu N, Zhang J and Zhao L (2024) Corrigendum: PCSK9i promoting the transformation of AS plaques into a stable plaque by targeting the miR-186-5p/Wipf2 and miR-375-3p/Pdk1/Yap1 in ApoE–/– mice. Front. Med. 11:1416622. doi: 10.3389/fmed.2024.1416622

Received: 12 April 2024; Accepted: 24 May 2024;
Published: 04 June 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Zhao, Liu, Zhang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lei Zhao, emhhb2xlaTA1MTgmI3gwMDA0MDthbGl5dW4uY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.